Eli Lilly (NYSE: LLY) is poised for a critical earnings test on Wednesday, with investor attention squarely on its blockbuster diabetes and weight-loss medications. The company's shares edged up 2.2% in pre-market trading on Monday, recovering from an 8.6% decline over the previous five sessions. At the latest check, the stock was trading at $1,140.48, according to Wall Street Journal data.
Initial projections from Visible Alpha indicate that Mounjaro and Zepbound will account for roughly 98% of the company's expected second-quarter revenue growth. Combined sales for the two drugs are forecast at $13.54 billion, representing approximately 65.7% of Lilly's projected total revenue of $20.62 billion. This marks a significant increase from the same period last year, when the franchise generated $8.58 billion, or 55.2% of revenue.
The upcoming report comes at a time when Lilly's valuation reflects high expectations. At Tuesday's close, the company boasted a market capitalization of $1.05 trillion with a trailing price-to-earnings multiple of 40.2 times. Options markets are pricing in a potential move of about 6% in the stock following the earnings release, underscoring the significance of the announcement.
Investors will be closely watching whether Lilly can maintain its growth momentum amid pricing pressures and supply constraints. In the first quarter, volume surged 65%, but a 13% decline in realized prices partially offset those gains. Gross margin slipped 0.6 percentage points to 81.9%, highlighting the balancing act between expanding sales and protecting profitability.
A key benchmark will be the company's full-year revenue guidance, which currently stands between $82 billion and $85 billion. An upward revision would signal confidence that volume growth can outpace pricing headwinds. However, as evidenced by competitor Novo Nordisk (NYSE: NVO), merely meeting expectations may not be sufficient. Novo's U.S.-listed shares dropped 6% on Tuesday despite raising its full-year outlook, as investors sought more decisive wins.
Pipeline developments add another layer of intrigue. Lilly recently granted restricted early access to its experimental obesity drug retatrutide for select patients, with an FDA submission targeted for the first quarter of 2027. While this program won't contribute to near-term revenue, it could shape the company's long-term competitive position.
Analysts will also scrutinize sales concentration, which has risen sharply. The two drugs now account for nearly two-thirds of total revenue, up from 55.2% a year ago and 64.8% last quarter. This concentration raises questions about the sustainability of growth and the performance of Lilly's other product lines, which are projected to grow only 1.5% year-over-year.
Wednesday's investor conference call, scheduled for 10:00 a.m. EDT, will be the primary catalyst for the week. Market participants are expected to focus on guidance, net pricing trends, manufacturing capacity, and margin dynamics rather than just headline sales figures. The key risk remains that faster-than-expected price declines could outpace prescription growth, while supply constraints or higher launch costs could also weigh on the premium valuation.
As Lilly prepares to report, the broader market narrative centers on whether the company can demonstrate that its leading franchise can continue to expand while maintaining profitability and not overshadowing other assets. The results will not only shape Lilly's near-term trajectory but also influence sentiment across the entire GLP-1 drug sector.
